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Abstract
Increases in the levels and/or activity of nonreceptor
tyrosine kinases c-Src and c-Yes are often associated
with colorectal carcinogenesis. The physiological con-
sequences of increased c-Yes activity during the early
and late stages of tumorigenesis, in addition to the
degree of redundancy between c-Yes and c-Src in colo-
rectal cancer cells, remain elusive. To study the con-
sequences of increases in c-Yes levels and activity in
later stages of colorectal carcinogenesis, we devel-
oped human colorectal cancer cell lines in which c-Yes
levels and activity can be inducibly increased by a
tightly controlled expression of wild-type c-Yes or by
constitutively active mutants of c-Yes, c-YesY537F,
and c-Yes#t6aa. c-Yes induction resulted in increased
cell motility but did not promote proliferation either
in vitro or in vivo. These results suggest that in later
stages of colorectal carcinogenesis, elevations in c-
Yes levels/activity may promote cancer spread and
metastasis rather than tumor growth.
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Introduction
The Src family of nonreceptor tyrosine kinases (SFK) con-
sists of ninemembers (c-Src, c-Yes, Fyn, Lck, Lyn, Hck, Fgr,
Blk, and Yrk). Three of them—c-Src, c-Yes, and Fyn—are
ubiquitously expressed, whereas the expression of others
is more restricted, mainly to cells of hematopoietic origin [1].
c-Src and c-Yes are proteins with molecular masses of 60
and 62 kDa, respectively. They have been reported to
regulate many signaling pathways involved in the control
of cell proliferation, survival, differentiation, adhesion, and
motility [1]. In addition to tyrosine kinase activity, c-Src and
c-Yes can also act as scaffolds for protein–protein interac-
tions. Both kinase-dependent and kinase-independent
functions of c-Src and c-Yes are regulated bymultiple mech-
anisms and contribute to a broad spectrum of cellular
processes in a variety of cell types [1]. Abnormal levels
and/or catalytic activities of c-Src and c-Yes have been
found in a number of human tumors, including lung, breast,
ovarian, gastric, and colorectal tumors [2,3].
c-Src has been reported to be upregulated in > 70% of
colorectal cancers, and levels of this protein increase in the
course of tumor development, being highest in metastatic
malignancies [4–7]. Upregulation of c-Yes is less frequent
and has been reported in about 50% of colorectal carcinomas
[8]. Importantly, however, an elevated expression of the c-yes
gene has been linked to malignancy of human colorectal
carcinoma by parametric clustering of quantitative expression
data [9], and, in the case of liver metastases, patients with
increased c-Yes activity had a shorter survival time when
compared with patients without c-Yes activation [10].
Although c-Src and c-Yes share significant sequence and
structural homology, they serve not only redundant but also
distinct functions, and consequences of their activation may
differ in diverse cellular backgrounds [11]. For example, acti-
vation of c-Yes is known to be associated with the formation of
tight junctions in canine kidney epithelial cells, whereas acti-
vation of c-Src is believed to be involved in the dissociation of
these structures [12].
A few investigations have analyzed the consequences of
increases in c-Src levels and activity on the growth of human
colorectal cancer cells [13–15]. Unfortunately, there are no
complementary mechanistic studies on the consequences of
c-Yes upregulation. Therefore, considering strong evidence cor-
relating c-Yes deregulation to the pathology of colorectal cancer,
there is a pressing need to elucidate the functions of c-Yes in
colorectal cancer cells. Moreover, published reports suggest
that c-Yes and c-Src may be differentially regulated and may
perform different functions in this cellular background [16].
Here we describe the construction of colorectal cancer cell
lines in which the levels and activity of c-Yes can be increased
Address all correspondence to: Arkadiusz Welman, PhD, or Caroline Dive, PhD, Clinical and
Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of
Manchester, Wilmslow Road, Manchester M20 4BX, UK. E-mail: awelman@picr.man.ac.uk or
cdive@picr.man.ac.uk
1This article refers to supplementary material, which is designated by ‘‘W’’ (i.e., Figure W1)
and is available online at www.bcdecker.com.
2This study was supported by a Cancer Research UK program grant (C147) to C. Dive.
Received 30 May 2007; Revised 4 July 2007; Accepted 6 July 2007.
Copyright D 2007 Neoplasia Press, Inc. All rights reserved 1522-8002/07/$25.00
DOI 10.1593/neo.07442
Neoplasia . Vol. 9, No. 9, September 2007, pp. 745–754 745
www.neoplasia.com
RESEARCH ARTICLE
by a tightly controlled inducible expression of wild-type (wt) c-
Yes or by constitutively active mutants of c-Yes. Functional
studies using these cell lines indicate that in more advanced
stages of colorectal carcinogenesis, increases in c-Yes level
and activity promote motility rather than cell proliferation and
tumor growth. These results may have important clinical
implications with respect to the substantial development
and clinical testing of SFK inhibitors as anticancer drugs
[17]. Furthermore, the results complement our previous
studies on the consequences of c-Src upregulation on colo-
rectal cancer cells [15].
Materials and Methods
Plasmid Vectors
Super module vectors pSMVLuc-wtYes, pSMVLuc-
Yes537F, and pSMVLuc-YesDt6aa are identical to the pre-
viously described pSMVLuc-Src527F plasmid [15], except
that they contain wtc-Yes, c-YesY537F, or c-YesDt6aa, re-
spectively, instead of the c-SrcY527F mutant. They were
generated by AseI-based fusion of the pN1pbactin-rtTA2S-
M2-IRES-EGFP plasmid [18] and Dox-inducible modules
derived from pBILuc-wtYes, pBILuc-Yes537F, and pBILuc-
YesDt6aa plasmids. The pBILuc-wtYes, pBILuc-Yes537F,
and pBILuc-YesDt6aa vectors are identical to the previously
described pBILuc-Src527F plasmid [18], except that the
coding sequence for the c-SrcY527F mutant has been
replaced with coding sequences for wtc-Yes, c-YesY537F,
or c-YesDt6aa, respectively.
Cell Culture, Transfections, and Selection of Stable
Cell Lines
LS174T, DLD-1, HT29, LoVo, WiDr, and Caco cells were
grown in RPMI 1640 medium. HCT116 cells were grown in
McCoy’s 5A medium. SW480, SW620, and Int407 cells were
grown in DMEM. All media (Gibco/Invitrogen, Paisley, UK)
were supplemented with 10% fetal calf serum, 100 U/ml
penicillin, and 100 mg/ml streptomycin.
The transfection and selection of stable cell lines suitable
for the Dox-inducible expression of wtc-Yes, c-YesY537F, c-
YesDt6aa, and luciferase were performed as described
previously [19].
Doxycycline Treatments
Doxycycline (Dox) was obtained fromClontech (Palo Alto,
CA; cat. no. 8634-1) and stored at20jC as a 2-mg/ml stock
in ddH2O.
Cells were plated out at 1  106 cells/3 ml of medium per
well in six-well plates (Costar 3516; Corning, Corning, NY).
After 20 to 24 hours, the medium was replaced with 3 ml of
fresh medium with or without 2 mg/ml Dox. Detached and ad-
herent cells were counted 24 to 30 hours later using a Coulter
particle counter Z1 (Beckman Coulter, High Wycombe, UK).
Alternatively, the cells were dissolved directly in Laemmli
sample buffer (Bio-Rad Laboratories, Hercules, CA; cat. no.
161-0737) or cell lysis buffer (Cell Signaling, Danvers, MA;
cat. no. 9803), and lysates were analyzed by SDS-PAGE
and Western blot analysis.
Four-day ± Dox growth curves were determined after
seeding cells at 4  105/3 ml of medium per well in six-well
plates. After 24 hours (day 1), the medium was replaced with
3 ml of fresh medium with or without 0.5 mg/ml Dox, and the
cells were counted daily for a period of 3 days using a Coulter
particle counter.
Cell Cycle Analysis
Cell cycle analysis was performed as previously de-
scribed [15].
‘‘Wound-Healing’’ Motility Assay
For wound-healing assays, cells were seeded at 1 
106 cells/1.5 ml of medium per well in 24-well plates (Multiwell
353047; Becton Dickinson, Franklin Lakes, NJ). After 24 hours,
the medium was replaced with 1.5 ml of fresh medium with or
without 0.5 mg/ml Dox. After a further 2 hours, the medium
was removed, and ‘‘wounds’’ were made by scratching cell
monolayers with P200 automatic pipette tips. To remove cellu-
lar debris, the cells were washed twice with tissue-culture
medium with or without 0.5 mg/ml Dox. Subsequently, 1.5 ml
of L-15 (Leibovitz) medium (Gibco/Invitrogen) with or without
0.5 mg/ml Dox and supplemented with 10% fetal calf serum,
100 U/ml penicillin, and 100 mg/ml streptomycin was placed
in each well. The closure of wounds by cell migration was
monitored at 37jC for 48 hours, with photographs taken every
10 minutes. The cells were observed under an inverted micro-
scope (Zeiss Axiovert 200M; Carl Zeiss, Welwyn Garden
City, UK) equipped with an Achroplan 10 objective with NA
0.25 (Carl Zeiss). Images were recorded with a cooled slow-
scanning charge-coupled device camera (CoolSnapHQ; Roper
Scientific, Harlow, UK) controlled by the image processing
program Metamorph (Universal Imaging, West Chester, PA).
Antibodies, Gel Electrophoresis, and Western
Blot Analysis
SDS-PAGE was performed using 10% polyacrylamide
gels. Proteins were blotted onto polyvinylidene fluoride mem-
branes (Perkin-Elmer, Boston, MA) and incubated with the
appropriate primary antibody and horseradish peroxidase–
coupled anti-mouse or anti-rabbit secondary IgG (Dako,
Glostrup, Denmark). The following primary antibodies were
used: monoclonal mouse anti-Yes, clone 1B7 (Wako, Osaka,
Japan; cat. no. 013-14261); monoclonal mouse anti-Src,
clone GD11 (Upstate, Chandlers Ford, UK; cat. no. 05-184);
monoclonal mouse anti-Fyn, clone Fyn301 (Wako; cat. no.
019-14241); polyclonal rabbit anti-Lck (Cell Signaling; cat. no.
2752); monoclonal mouse anti-phosphotyrosine, clone 4G10
(Upstate; cat. no. 05-321); and monoclonal mouse anti-actin
(Sigma, Poole, UK; cat. no. A-4700).
Tumor Xenografts
LS174T Luc-wtYes 17 and LS174T Luc-Yes537F 29 cells
were grown as subcutaneous xenografts in 8-week-old fe-
male Balb/c-NUDE nude mice (Paterson Institute for Cancer
Research, Manchester, UK) following the injection of 1 
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107 cells in 0.1 ml of Optimem (Gibco/Invitrogen; cat. no.
51985-026). Mice were housed in an individually ventilated
caging system on a 12-hour light/dark environment main-
tained at constant temperature and humidity. The mice
were fed a standard diet (controls) or a Dox-containing diet
(625 mg/kg TD 01306; Harlan-Teklad, Madison, WI), as
described [20]. Tumor volume (length  width2/2) was mea-
sured every 2 days. When tumors approached the legal
maximum tumor volume, the mice were sacrificed. Following
dissection, the tumors were halved. One half was snap
frozen for subsequent luciferase reporter assay. The other
half, to be used subsequently for immunochemistry analysis,
was immediately placed in 4% formalin. After 24 hours, 4%
formalin was removed and replaced with 70% ethanol. All
procedures were carried out in accordance with UK Coordi-
nating Committee on Cancer Research guidelines by ap-
proved protocol (Home Office Project license no. 40-2746).
Immunohistochemistry
Immunohistochemistry was performed using monoclo-
nal mouse antibody against human Ki67 antigen (Dako;
cat. no. M7240), and monoclonal mouse IgG1 against
Aspergillus niger glucose oxidase (Dako; cat. no. X0931)
was used as a negative control. Tumor samples were
imbedded in Paraplast wax (McCormick Scientific, St. Louis,
MO; cat. no. 501006) using Histolette II cassettes (Simport
Plastics, Bernard-Pilon Beloeil, Canada; cat. no. M493).
They were sliced using a microtome (4-mm sections) and
mounted onto superfrosted microscope slides (76  26 mm;
Menzel-Glasser, Braunschweig, Germany). [The micro-
scope slides were immersed for 5 minutes in a 2% solution
of (3-aminopropyl)triethoxysilane (Sigma; cat. no. A3648)
in acetone and dried at 45jC for 2 hours before mounting
cut paraffin sections.] For dewaxing and rehydration, slides
were bathed in xylene (twice, 5 minutes each), 100% ethanol
(four times, 1 minute each), 90% ethanol (for 1 minute),
70% ethanol (for 1 minute), and tap water (for 1 minute).
They were then placed in 10 mM citric acid–NaOH (pH 6.0),
heated in microwave for 25 minutes, allowed to cool down
to room temperature (RT;f 15 minutes), and bathed in tap
water. To deactivate endogenous peroxidase within the sec-
tions, the slides were immersed for 30 minutes in PBS
containing 0.3% hydrogen peroxide. The slides were placed
in humidified Immuno Slide staining trays (Raymond a
Lamb, Eastbourne, UK; cat. no. E103.2). Mounted sections
were ‘‘outlined’’ using ImmEdge pen (Vector Laboratories,
Burlingame, CA; cat. no. H-4000) to prevent the spill of the
solutions to be used later, and each section was covered
with a droplet of PBS. Subsequently, the sections were
treated with the following solutions (100 ml of each solution
was used per section): casein solution (Vector Laboratories;
cat. no. SP-5020) in PBS for 1 hour at RT; low-cross buffer
(Candor Bioscience, Weissensberg, Germany; cat. no.
100050) for 30 minutes at RT; primary antibody solution
(1:25 dilution of Ki67 antibody in casein solution in PBS; a
1:1000 dilution of IgG against glucose oxidase from A. niger
was used in negative controls) overnight at 4jC; PBS twice
for 5 minutes at RT; secondary antibody solution [1:1000
dilution of anti-mouse IgG antibody (from Vectastain ABC
mouse IgG kit; Vector Laboratories; cat. no. PK4002) in
PBS] for 30 minutes at RT; PBS twice for 5 minutes at
RT; Vectastain ABC reagent (from Vectastain ABC mouse
IgG kit) for 30 minutes at RT; PBS twice for 5 minutes at
RT; and DAB solution (Vector Laboratories; cat. no. SK4100)
for 10 minutes at RT (this is the final ‘‘visualization’’ step).
Sections were then counterstained with hematoxylin, dehy-
drated in increasing concentrations of ethanol [70%, 90%,
and 100% (3), 1 minute each], and then immersed in
xylene for 5 minutes. This was followed by the mounting of
glass coverslips and microscopic analysis.
Figure 1. Expression levels of selected Src family kinases in human colorectal cancer cell lines. Western blot analysis comparing the endogenous protein levels of
c-Yes, c-Src, Fyn, and Lck in nine colorectal cancer cell lines (HCT116, LoVo, DLD-1, HT-29, Caco-2, LS174T, WiDr, SW480, and SW620). Int407 is a nontrans-
formed human intestinal epithelial cell line. Data are representative of three independent experiments.
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Figure 2. Properties of LS174T clones engineered for inducible expression of wtc-Yes, c-YesY537F, or c-YesDt6aa. (A) The upper panel shows Western blot
analyses illustrating the expression of indicated c-Yes constructs 24 hours following Dox-triggered induction in engineered LS174T Luc-wtYes, LS174T Luc-
YesY537F, and LS174T Luc-YesDt6aa cell lines. Parental wild-type LS174T cells and LS174 Luc-only B20 cells have been included as controls. The lower panel
directly compares endogenous c-Yes levels in selected colon cancer cell lines with the levels of c-Yes observed in some of the engineered LS174T clones in the
presence and in the absence of induction. Data are representative of three independent repeat experiments. (B) Western blot analysis of total tyrosine phos-
phorylation in representative LS174T Luc-wtYes, LS174T Luc-YesY537F, and LS174T Luc-YesDt6aa clones after 24 hours of growth in the presence or in the
absence of Dox. Parental wild-type LS174T cells and LS174 Luc-only B20 cells have been included as controls. Data are representative of three independent
repeat experiments. (C) Growth characteristics of parental wild-type LS174T cells, LS174T Luc-only control cells, and selected LS174T Luc-wtYes, LS174T Luc-
YesY537F, and LS174T Luc-YesDt6aa clones in the absence of Dox. Growth curves were determined after seeding 1  105 cells/well in six-well plates. Data are
representative of three independent experiments performed in triplicate.
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Figure 3. Consequences of the induction of wtc-Yes, c-YesY537F, and c-YesDt6aa on the growth of LS174T cells in vitro. (A) Quantification of adherent and
detached cells in indicated LS174T Luc-wtYes, LS174T Luc-YesY537F, LS174T Luc-YesDt6aa clone, LS174T Luc-only control clone, and parental wild-type
LS174T cell line after 24 hours of growth in the presence or in the absence of Dox. Data are representative of three independent experiments performed in
triplicate. (B) Four-day growth curves of LS174T Luc-wtYes clone 17, LS174T Luc-Yes537F clone 14, LS174T Luc-YesDt6aa clone 23, and LS174T Luc-only
control cells (clone B20) in the absence and in the presence of Dox. Data are representative of three independent experiments performed in triplicate.
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Results
Characterization of c-Yes, c-Src, Fyn, and Lck Levels
in Colorectal Cancer Cell Lines
We analyzed the protein levels of the three ubiquitously
expressed members of the Src family (c-Yes, c-Src, and Fyn)
in a panel of nine colorectal cancer cell lines. Considering that
it has been previously reported that abnormal expression of
Lck can sometimes occur during colorectal carcinogenesis
[21], we also determined the expression levels of thismember
of the Src family. As illustrated in Figure 1, diverse but sig-
nificant levels of c-Yes, c-Src, and Fyn could be detected in all
colorectal cancer cell lines tested. They were usually higher
than the levels observed in the nontransformed human
intestinal epithelial cell line Int407. Lck was abundant in
SW620 cells and detectable in LoVo and SW480 cells. No
detectable expression of Lck was seen in the other cell lines
analyzed. These results complement previously published
studies on SFK expression in colorectal cancer cell lines [22].
Generation of Colorectal Cancer Cell Lines for
Dox-Regulated Expression of wtc-Yes and
Constitutively Active Mutants of c-Yes
Considering the fact that LS174T cells displayed the
lowest level of endogenous c-Yes out of all the colorectal
cancer cell lines analyzed (Figure 1), we have chosen this
cell line as a primary model in which to investigate the
consequences of increases in the levels and activity of this
protein. HCT116 cells have been selected as a secondary
model because we have previously performed extensive
studies on the consequences of c-Src upregulation on the
growth of this colorectal cancer cell line [15]. The use of
HCT116 cells enabled a direct comparison between the
effects of c-Yes and c-Src in the same cellular background.
Based on structural similarities between c-Yes and the
more extensively studied c-Src kinase, we designed two
mutants of c-Yes, c-YesY537F and c-YesDt6aa. In the c-
YesY537F mutant, the tyrosine residue at position 537 has
been substituted by phenylalanine. In the c-YesDt6aamutant,
six C-terminal amino acids directly following tyrosine-537
have been removed. When phosphorylated, tyrosine-537 is
believed to be essential for keeping the protein in an inactive
closed conformation. Analogous mutations in c-Src resulted in
a constitutively active open conformation of the protein
[23,24]; thus, we expected c-YesY537F and c-YesDt6aa
mutants to be constitutively active.
The coding sequences of both wtc-Yes and generated
mutants of c-Yes have been integrated with the components
of the recently described rapid single-step nonviral system
for inducible gene expression to construct vectors suitable
for a simultaneous Dox-dependent expression of c-Yes
protein (wild type or mutant) and firefly luciferase serving
as a reporter [15]. The vectors have been subsequently used
to generate LS174T and HCT116 cell lines capable of an
inducible expression of luciferase and wtc-Yes, c-YesY537F,
or c-YesDt6aa in the presence of Dox (Figures 2A and
W1A). Cell clones suitable for inducible expression of only
the luciferase reporter have also been developed to serve
as controls. All the cell clones selected for further investiga-
tions displayed growth properties similar to their respective
parental cell line in the absence of induction (Figures 2C
and W1C). Importantly, inducible expression of c-YesY537F
and c-YesDt6aa mutants resulted in highly increased intra-
cellular phosphotyrosine levels, confirming that these mu-
tants were indeed constitutively active as predicted (Figures
2B and W1B).
Inducible Increases in c-Yes Levels and Activity
Do Not Promote the Proliferation of LS174T
and HCT116 Cells In Vitro
We examined the consequences of the induction of wtc-
Yes, c-YesY537F, and c-YesDt6aa on the growth of LS174T
Figure 4. Consequences of inducible increases in c-Yes levels and activity on the cell cycle profile of LS174T cells. Histogram illustrates the percentage of cells
in each cell cycle phase after 24 hours of growth in the presence and in the absence of Dox. Means and standard deviations are based on data from three
independent experiments.
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and HCT116 cells. As shown in Figures 3 and W2, we were
unable to detect any growth-promoting effects of any of the
c-Yes constructs within 24 to 72 hours of induction. If any-
thing, overexpression of c-YesY537F, c-YesDt6aa, and wtc-
Yes could be slightly growth-inhibitory. These results were
consistent with almost identical cell cycle profiles between
investigated clones in induced (+Dox) and uninduced (Dox)
states (Figures 4 and W3). We did not observe any changes
in cell viability following the induction of wtc-Yes or of the
constitutively active mutants of c-Yes (Figure W4).
Inducible Increases in c-Yes Levels and Activity
Do Not Promote the Growth of LS174T
Tumor Xenografts
The experiments described so far demonstrated that
increases in the levels and activity of c-Yes do not promote
the proliferation of LS174T and HCT116 cells in vitro. To
assess the consequences of Yes upregulation on cell growth
in a more complex in vivo microenvironment, we grew
LS174T clones inducing wtc-Yes and constitutively active
c-YesY537F mutant (LS174T Luc-wtYes 17 and LS174T
Luc-YesY537F 29) as xenografts in nude mice. As illustrated
in Figure 5, neither induction of wtc-Yes nor induction of
c-YesY537F resulted in any growth-promoting effects on
LS174T tumor xenografts. Immunohistochemistry studies
performed on tumor sections using antibody specific for
the proliferation marker Ki67 also did not detect any signif-
icant differences in cell proliferation following wtc-Yes or
cYesY537F induction (Figure 5).
Induction of c-Yes Results in Increased Motility
of LS174T Cells
Considering that c-Src is known to promote cell motility (a
process believed to be important for the metastatic spread
Figure 5. Consequences of the induction of wtc-Yes and c-YesY537F on the growth of LS174T cells in a xenograft model. LS174T Luc-wtYes 17 cells (A) and
LS174T Luc-YesY537F 29 cells (B) were grown in vivo as described in the Materials and Methods section. There were at least five animals in each control group
and Dox-treated group. Top panels show the growth curves for each clone in the presence and in the absence of Dox. Successful gene induction in Dox-treated
animals was confirmed using luciferase reporter assay (histogram inserts in the top panels). The percentages of cells positive for the proliferation marker Ki67
scored following immunochistochemistry studies on xenograft sections and representative photographs of staining are shown in bottom panels. Ki67 staining was
performed as described in the Materials and Methods section.
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of cancer cells) and that c-Yes has been reported to be ele-
vated in colorectal cancer metastases to the liver, we ana-
lyzed the effects of inducible elevations in c-Yes levels and
activity on the motility of LS174T cells in a commonly used
wound-healing assay [25]. As illustrated in Figure 6, induc-
tion of wtc-Yes resulted in a clear increase in cell migration
into the wound (representative images of migrating cells are
shown in Figure W5). The effect was even more pronounced
in the clones induced to express the constitutively active
mutants of c-Yes. No increases in cell motility following Dox
treatment were observed in control LS174T Luc-only cells
(clone B20) and in the parental LS174T cell line.
Discussion
There is considerable evidence linking the aberrant signaling
of nonreceptor tyrosine kinases from the Src family (SFK) to
the development and progression of a variety of human tu-
mors [2,3]. Consequently, SFK is believed to be an attractive
target for cancer chemotherapy, and multiple SFK inhibitors
have been developed [26]. Some of these inhibitors have re-
cently entered phase I clinical trials as anticancer agents
[17]. The success of Src-focused therapeutic strategies
depends on a thorough understanding of SFK functions in
relevant human cancer cell contexts. Unfortunately, the con-
sequences of abnormal signaling from SFK and the degree
of redundancy between particular members of the Src family
are still poorly defined for the majority of human tumor types.
We have previously performed a detailed analysis of the
consequences of increases in c-Src levels and activity on the
growth of human colorectal cancer cells in vitro and in vivo
[15]. In the present study, we characterized the effects of c-
Yes upregulation on LS174T and HCT116 cells. Our results
demonstrate that elevations in c-Yes levels and activity
promote the motility of colorectal cancer cells but are unable
to promote their proliferation. These data support the hy-
pothesis that in more advanced stages of colorectal carci-
nogenesis, increases in the levels and activity of SFKmay be
involved in tumor spread and metastasis rather than in the
direct promotion of tumor growth. Of course, we cannot ex-
clude the possibility that elevations in c-Yes (or other mem-
bers of the SFK) may trigger increased proliferation in some
other colorectal cancer cell types, but in the context of our
results, proliferation is unlikely to be a common response to
SFK upregulation. This assumption finds strong support in a
recent study by Serrels et al. [27], in which the SFK inhibitor
dasatinib (BMS-354825), when used at concentrations suf-
ficient to block the kinase activity of SFK, was shown to have
no effect on the proliferation of 10 of 12 colorectal cancer cell
lines tested. Consequently, it is tempting to speculate that in
Figure 6. Effects of inducible increases in c-Yes levels and activity on the
motility of LS174T cells characterized in a wound-healing assay. The assay
was performed as described in the Materials and Methods section. Graphs
show a quantitative analysis of the wound-healing process. They illustrate
changes in ‘‘wound’’ width (presented as a percentage of the initial wound
width) in time. Means and standard deviations are based on three indepen-
dent experiments performed in quadruplicate.
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advanced colorectal carcinomas, SFK inhibitors may be
more effective in suppressing other processes (e.g., invasion
and metastasis) than in suppressing tumor growth. It is still
possible, however, that SFK could promote cell proliferation
at earlier phases of colorectal carcinogenesis (e.g., at dys-
plastic epithelium stage). This possibility is supported by
observations that certain downstream effectors of SFK are
able to promote the growth of colorectal cancer cells [28,29].
Undoubtedly, additional studies on the roles of SFK at
diverse stages of colorectal carcinogenesis are necessary
to optimize the use of SFK inhibitors in colorectal cancer
therapy in the clinic.
A different aspect of our study is the issue of common and
distinct functions of c-Yes and c-Src in colorectal cancer
cells. It is interesting to notice that, despite relatively high
expression levels of the constitutively active c-Yes mutants
following induction in some of the generated HCT116 clones,
we did not observe cell detachment, formation of large
vesicular structures in the cytoplasm, nonapoptotic cell
death, nor delay in the G2 phase of the cell cycle, which
have been previously reported to be associated with high-
level induction of the constitutively active c-Src mutant c-
SrcY527F [15]. Although the reasons for these apparent
differences in phenotype following high-level induction of
c-SrcY527F and c-YesY537F remain unknown, it seems
reasonable to assume that they reflect some intrinsic differ-
ences between c-Src and c-Yes signaling. It has been
reported that c-Yes and c-Src are differentially regulated
during the cell cycle progression of colorectal carcinoma
cells [16]. Studies in fibroblasts indicate that c-Yes is unable
to compensate for c-Src signaling in several processes that
require dynamic regulation of the actin cytoskeleton and
that this can be attributed to the diverse structure of SH4-
Unique-SH3-SH2 domains of these proteins [30]. Differ-
ences in c-Src and c-Yes signaling with respect to a variety
of intracellular processes have also been described in sev-
eral other cell types (reviewed in Summy et al. [11]). In the
context of these published reports and in the light of our
observations, potential differences between c-Src and c-Yes
signaling in colorectal cancer cells deserve further attention.
c-Src signaling is well known to promote cell motility in
multiple cellular backgrounds, including colorectal cancer
cells [31]. Our data provide evidence that in a colorectal
cancer cell background, c-Yes activation is also associated
with increases in cell motility. Although the contribution of
these c-Yes– induced increases in cell motility to cancer
invasion and metastasis requires further evaluation, it is
tempting to speculate that inhibitors of SFKmay prove useful
as antimetastatic agents.
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Figure W1. Properties of HCT116 clones engineered for inducible expression of wtc-Yes, c-YesY537F, or c-YesDt6aa. (A) Western blot analyses illustrating the
expression of indicated c-Yes constructs 24 hours following Dox-triggered induction in engineered HCT116 Luc-wtYes, HCT116 Luc-YesY537F, and HCT116 Luc-
YesDt6aa cell lines. Parental wild-type HCT116 cells and HCT116 Luc-only B20 cells have been included as controls. Data are representative of three independent
repeat experiments. (B) Western blot analysis of total tyrosine phosphorylation in representative HCT116 Luc-wtYes, HCT116 Luc-YesY537F, and HCT116 Luc-
YesDt6aa clones after 24 hours of growth in the presence or in the absence of Dox. Parental wild-type HCT116 cells and HCT116 Luc-only B20 cells have been
included as controls. Data are representative of three independent repeat experiments. (C) Growth characteristics of parental wild-type HCT116 cells, HCT116
Luc-only control cells, and selected HCT116 Luc-wtYes, HCT116 Luc-YesY537F, and HCT116 Luc-YesDt6aa clones in the absence of Dox. Growth curves were
determined after seeding 1  105 cells/well in six-well plates. Data are representative of three independent experiments performed in triplicate.
Figure W2. Consequences of the induction of wtc-Yes, c-YesY537F, and c-YesDt6aa on the growth of HCT116 cells in vitro. (A) Quantification of adherent and
detached cells in indicated HCT116 Luc-wtYes, HCT116 Luc-YesY537F, HCT116 Luc-YesDt6aa clones, HCT116 Luc-only control clone, and parental wild-type
HCT116 cell line after 24 hours of growth in the presence or in the absence of Dox. Data are representative of three independent experiments performed in
triplicate. (B) Four-day growth curves of HCT116 Luc-wtYes clone 28, HCT116 Luc-Yes537F clone 1, HCT116 Luc-YesDt6aa clone 21, and HCT116 Luc-only
control cells (clone B20) in the absence and in the presence of Dox. Data are representative of three independent experiments performed in triplicate.
Figure W3. Consequences of inducible increases in c-Yes levels and activity on the cell cycle profile of HCT116 cells. Histogram illustrates the percentage of cells
in each cell cycle phase after 24 hours of growth in the presence and in the absence of Dox. Means and standard deviations are based on data from three
independent experiments.
Figure W4. Effects of the induction of wtc-Yes, c-YesY537F, and c-YesDt6aa on the viability of LS174T and HCT116 cells. (A) Percentages of dead cells in
indicated LS174T clones and parental wild-type LS174T cells estimated using trypan blue exclusion method after 24 hours of growth in the presence or in the
absence of induction. Data are representative of three repeat experiments performed in triplicate. (B) Percentages of dead cells in indicated HCT116 clones and
parental wild-type HCT116 cells estimated using trypan blue exclusion method after 24 hours of growth in the presence or in the absence of induction. Data are
representative of three repeat experiments performed in triplicate.
Figure W5. Representative images from the wound-healing assay illustrating cell migration into the wound for indicated cell lines in the presence and in the
absence of Dox after 48 hours. Quantitative data for the wound-healing assay are provided in Figure 6.
